Display options
Cite
Boura P, Tselios K, Skendros P, et al. Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia. 2007;11(4):210-5
Boura, P., Tselios, K., Skendros, P., Kamali, S., Sarantopoulos, A., & Raptopoulou-Gigi, M. (2007). Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia, 11(4), 210-5.
Boura, P, et al. "Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center." Hippokratia vol. 11,4 (2007): 210-5.
Boura P, Tselios K, Skendros P, Kamali S, Sarantopoulos A, Raptopoulou-Gigi M. Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center. Hippokratia. 2007 Oct;11(4):210-5. PMID: 19582197; PMCID: PMC2552987.
Copy Download .nbib Format: NLM
Share it on

Hippokratia. 2007 Oct;11(4):210-5.

Adamantiades-Behcet disease (ABD) in northern Greece patients: experience from a single center.

Hippokratia

P Boura, K Tselios, P Skendros, S Kamali, A Sarantopoulos, M Raptopoulou-Gigi

Affiliations

  1. Clinical Immunology Unit, 2nd Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. [email protected]

PMID: 19582197 PMCID: PMC2552987

Abstract

UNLABELLED: OBJECTIVE-METHODS: Adamantiades-Behcet disease (ABD) is a multi-systemic vasculitis of unknown origin, with a characteristic geographic distribution, that affects vessels of all kinds and sizes and is characterized by recurrent mucosal, skin and ocular lesions. In the present study, a series of 36 patients from Northern Greece is analyzed retrospectively in regard to the epidemiological, clinical and immunological parameters.

RESULTS: All patients had recurrent oral ulcerations (36/36, 100%), while 23/36 (63.9%) experienced genital ulcerations and 22/36 (61.1%) developed ocular disease. Skin manifestations were observed in 23/36 patients (63.9%) and pathergy test was found positive in 14/36 patients (38.9%). Other manifestations included central nervous system involvement, recurrent genitourinary inflammations, arthralgias and superficial thrombophlebitis. Laboratory findings were not specific, partly reflecting the severity of inflammation. Ocular disease was more often observed in HLA-B51 (+) patients (20/31, 64.5%) than in HLA-B51 (-) patients. Standard of care (SOC) treatment consisted of cyclosporine A, azathioprine, methylprednisolone and aspirin, whereas refractory disease was treated with intravenous pulses of methylprednisolone and cyclophosphamide. Occasionally, anti-TNF agents (infliximab) were applied to treat refractory ocular disease.

CONCLUSION: The findings of the present study come in agreement with those reported for other Mediterranean series. HLA-B51 seems to predispose to more severe disease, while early therapeutic intervention is beneficial for these patients.

Keywords: Adamantiades-Behcet disease; HLA-B51; clinical manifestations; pathergy

References

  1. Semin Arthritis Rheum. 1998 Feb;27(4):197-217 - PubMed
  2. Neurol Sci. 2006 Dec;27(6):432-5 - PubMed
  3. Brain. 1999 Nov;122 ( Pt 11):2171-82 - PubMed
  4. Neurologist. 2005 Mar;11(2):80-9 - PubMed
  5. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S46-51 - PubMed
  6. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19-26 - PubMed
  7. Int J Dermatol. 2003 May;42(5):346-51 - PubMed
  8. Int J Dermatol. 2005 Aug;44(8):657-60 - PubMed
  9. Am J Ophthalmol. 2004 Sep;138(3):373-80 - PubMed
  10. Arch Ophthalmol. 1970 Oct;84(4):451-2 - PubMed
  11. Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii51-3 - PubMed
  12. Postgrad Med J. 2000 Oct;76(900):629-37 - PubMed
  13. J Rheumatol. 2000 Mar;27(3):703-7 - PubMed
  14. Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S96-105 - PubMed
  15. Hum Immunol. 1998 Apr;59(4):250-5 - PubMed
  16. J Eur Acad Dermatol Venereol. 2005 Jul;19(4):484-6 - PubMed
  17. Lancet. 2001 Jul 28;358(9278):295-6 - PubMed
  18. Br J Rheumatol. 1992 May;31(5):299-308 - PubMed
  19. J Neurol Sci. 2004 May 15;220(1-2):99-104 - PubMed
  20. Curr Opin Rheumatol. 1999 Jan;11(1):53-7 - PubMed
  21. Skinmed. 2005 Sep-Oct;4(5):282-6 - PubMed
  22. Lancet. 1990 May 5;335(8697):1078-80 - PubMed
  23. Clin Exp Med. 2004 Sep;4(1):10-20 - PubMed
  24. Semin Arthritis Rheum. 2001 Apr;30(5):299-312 - PubMed

Publication Types